Arabic Arabic English English French French German German
dark

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China

Viracta  Therapeutics, Inc. today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People’s Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

Next Post

LUNGevity Foundation and Partner Hamoui Family Foundation Issue 2022 Request for Applications for RET-Positive Clinical Lung Cancer Research

Related Posts
Total
0
Share